Interferon Alfa–Induced Adverse Effects in Patients with a Psychiatric Diagnosis
- 11 July 2002
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 347 (2) , 148-149
- https://doi.org/10.1056/nejm200207113470221
Abstract
Two reports in the Journal 1,2 have suggested that patients who have psychopathologic symptoms before beginning interferon alfa therapy may have more severe adverse psychiatric effects in response to treatment. This suggestion was based on the observation that patients' scores on psychopathologic rating scales before interferon alfa therapy were positively correlated with the scores after four weeks of treatment.1,2 However, we and others have found that patients with a psychiatric diagnosis can successfully complete interferon alfa therapy.3,4 An editorial in the Journal has rightly emphasized that withholding interferon alfa inappropriately, especially from members of a stigmatized class, “raises questions about fairness and discrimination.”5Keywords
This publication has 4 references indexed in Scilit:
- Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users?New England Journal of Medicine, 2001
- Paroxetine for the Prevention of Depression Induced by High-Dose Interferon AlfaNew England Journal of Medicine, 2001
- Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disordersThe Lancet, 1999
- Prediction of the Depressive Effects of Interferon Alfa Therapy by the Patient's Initial Affective StateNew England Journal of Medicine, 1999